Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 01/07/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 91 publications

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; encorafenib for colorectal cancer, daratumumab for multiple myeloma, repotrectinib for NTRK-fusion positive solid tumors, and venetoclax for leukemia.

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; encorafenib for colorectal cancer, daratumumab for multiple myeloma, repotrectinib for NTRK-fusion positive solid tumors, and venetoclax for leukemia.

Journal: International journal of clinical oncology
Published: December 15, 2025

Rare but not forgotten: Therapeutic advancements for rare childhood cancers.

Rare but not forgotten: Therapeutic advancements for rare childhood cancers.

Journal: Molecular therapy. Oncology
Published: December 01, 2025

Lorlatinib in Tyrosine Kinase Inhibitor-Naive Advanced ROS1-Positive Non-Small Cell Lung Cancer: A Phase 2 Nonrandomized Clinical Trial.

Lorlatinib in Tyrosine Kinase Inhibitor-Naive Advanced ROS1-Positive Non-Small Cell Lung Cancer: A Phase 2 Nonrandomized Clinical Trial.

Journal: JAMA oncology
Published: November 26, 2025

KRAS-Wild Pancreatic Cancer-More Targets than Treatment Possibilities?

KRAS-Wild Pancreatic Cancer-More Targets than Treatment Possibilities?

Journal: Cancers
Published: October 29, 2025

Evolving Therapeutic Landscape of ROS1-Positive Non-Small Cell Lung Cancer: An Updated Review.

Evolving Therapeutic Landscape of ROS1-Positive Non-Small Cell Lung Cancer: An Updated Review.

Journal: Current oncology (Toronto, Ont.)
Published: October 15, 2025

The Utility of Tissue-Agnostic Drugs in Lung Cancer Treatment.

The Utility of Tissue-Agnostic Drugs in Lung Cancer Treatment.

Journal: Pharmaceutical medicine
Published: August 26, 2025

Taletrectinib (Ibtrozi) - another kinase inhibitor for non-small cell lung cancer (NSCLC).

Taletrectinib (Ibtrozi) - another kinase inhibitor for non-small cell lung cancer (NSCLC).

Journal: The Medical letter on drugs and therapeutics
Published: July 29, 2025

Recent advances in tropomyosin receptor kinase (TRK) inhibitors: a 2023-2024 patent landscape review.

Recent advances in tropomyosin receptor kinase (TRK) inhibitors: a 2023-2024 patent landscape review.

Journal: Expert opinion on therapeutic patents
Published: July 05, 2025

First Clinical Evidence of Repotrectinib Efficacy in ROS1-Rearranged NSCLC With a D2033N Resistance Mutation: Case Report.

First Clinical Evidence of Repotrectinib Efficacy in ROS1-Rearranged NSCLC With a D2033N Resistance Mutation: Case Report.

Journal: Clinical lung cancer
Published: June 13, 2025

Toxicity profiles of ROS1 tyrosine kinase inhibitors in advanced non-small cell lung cancer: a systematic review and proportional meta-analysis.

Toxicity profiles of ROS1 tyrosine kinase inhibitors in advanced non-small cell lung cancer: a systematic review and proportional meta-analysis.

Journal: Frontiers in pharmacology
Published: June 09, 2025

Advances in Tissue-Agnostic Targeting in Cancer Therapeutics: Current Approvals, Challenges, and Future Directions.

Advances in Tissue-Agnostic Targeting in Cancer Therapeutics: Current Approvals, Challenges, and Future Directions.

Journal: Oncology research
Published: May 13, 2025

Nociceptive sensory neuron-derived NGF orchestrates a fibrotic mesenchymal stromal cell neurogenic niche to drive tendon pathological fibrosis.

Nociceptive sensory neuron-derived NGF orchestrates a fibrotic mesenchymal stromal cell neurogenic niche to drive tendon pathological fibrosis.

Journal: Nature communications
Published: April 18, 2025
Showing 1-12 of 91

Last Updated: 01/07/2026